Anticholinergic antiparkinson agents

Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopamine deficiency in the nigrostriatal pathway, leading to motor symptoms such as bradykinesia, rigidity, tremor, and postural instability.

In addition to dopaminergic therapy (levodopa, dopamine agonists, MAO-B inhibitors), anticholinergic agents are employed as adjunctive treatments. These drugs act by restoring the balance between dopamine and acetylcholine in the basal ganglia. They are especially effective in tremor-predominant PD and in treating drug-induced parkinsonism from antipsychotics.

---

Mechanism of Action

• Target: Muscarinic acetylcholine receptors (primarily M1 subtype) in the striatum.

• Action: Blockade of muscarinic receptors reduces excitatory cholinergic transmission → restores balance with reduced dopaminergic signaling.

• Effect: Decreased tremor, rigidity, and drooling; minimal effect on bradykinesia.

---

Common Anticholinergic Antiparkinson Agents

1. Trihexyphenidyl

   • Most widely used in PD.

   • Oral administration, effective in tremor and rigidity.

2. Benztropine mesylate

   • Dual mechanism: antimuscarinic + weak inhibition of dopamine reuptake.

   • Also useful in treating acute dystonic reactions caused by antipsychotics.

3. Biperiden

   • Effective antimuscarinic, used in PD and drug-induced extrapyramidal symptoms.

4. Procyclidine

   • Similar to trihexyphenidyl, used for tremor and rigidity.

5. Orphenadrine

   • Less common; used for PD-related tremor and muscle rigidity.

---

Therapeutic Indications

1. Idiopathic Parkinson’s Disease (PD):

   • Best suited for patients with tremor-predominant PD.

   • Limited benefit for bradykinesia and postural instability.

2. Drug-Induced Parkinsonism:

   • Antipsychotic-induced extrapyramidal symptoms (EPS) such as dystonia, rigidity, tremor.

   • Benztropine and trihexyphenidyl are particularly useful.

3. Other Uses:

   • Drooling and sialorrhea in PD patients.

   • Occasionally used in combination with levodopa for synergistic effect (historically more common, less now due to cognitive side effects).

---

Contraindications

• Narrow-angle glaucoma: May precipitate acute angle closure.

• Urinary retention / prostatic hypertrophy: Risk of worsened retention.

• Gastrointestinal obstruction or paralytic ileus.

• Cognitive impairment or dementia: Worsens confusion and memory loss.

• Elderly patients: High risk of delirium, hallucinations, and falls.

---

Adverse Effects

Peripheral Anticholinergic Effects

• Dry mouth (xerostomia).

• Blurred vision, mydriasis.

• Constipation.

• Urinary retention.

• Tachycardia.

Central Nervous System Effects

• Confusion, memory impairment.

• Hallucinations, agitation, delirium (especially in elderly).

• Sedation or drowsiness in some cases.

---

Clinical Considerations

1. Patient Selection:

   • More effective in young patients with tremor-dominant PD.

   • Avoid or minimize use in elderly due to high risk of cognitive side effects.

2. Role in Therapy:

   • Used as adjuncts, not first-line.

   • Levodopa and dopamine agonists remain the mainstay; anticholinergics are add-on therapies in select patients.

3. Drug-Induced Parkinsonism:

   • First-line treatment, especially when discontinuation of the offending antipsychotic is not possible.

4. Dosing:

   • Start with low doses and titrate gradually to balance tremor control with adverse effects.

5. Combination Therapy:

• May be combined with dopaminergic agents but must be carefully monitored for additive adverse effects.